Ablaze Pharmaceuticals
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Ablaze Pharmaceuticals - overview
Established
2021
Location
Shanghai, -, China
Primary Industry
Biotechnology
About
Established in 2021 and based in Shanghai, China, Ablaze Pharmaceuticals is a biopharmaceutical company that focuses on research and development of radiotherapy drugs and Targeted Radiotherapy (TRT). The president and CEO Dr. Alex Qiao is the postdoctoral in biochemistry at the Massachusetts Institute of Technology, he co-founded and was CEO of NajingTech from 2008 to 2012 and has over 20 years of experience as an entrepreneur, business leader and technology innovator in the life sciences, biopharmaceutical and high-tech industries. The company is main business is research and development of radiotherapy drugs and Targeted Radiotherapy (TRT), technology development, technology consulting, technology service, technology transfer in the fields of medical technology and biotechnology, and wholesale and retail of first-class medical equipment.
The company plans to use the series A funding for establish a leading pipeline of advanced TRT products for the treatment of solid tumors, build a leadership team, and establish a radiopharmaceutical infrastructure.
Current Investors
Vivo Capital, VenBio, Advantech Capital
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals
Website
www.ablazepharma.com
Verticals
HealthTech
Company Stage
Series A
Total Amount Raised
Subscriber access only
Ablaze Pharmaceuticals - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.